companiesandmarkets.com

Return to Report | Print

Premium Company Profile - BioMarin Pharmaceutical Inc.

http://www.companiesandmarkets.com/Summary-Company-Profile/premium-company-profile-biomarin-pharmaceutical-inc.-41373.asp

Report Summary

Introduction

BioMarin Pharmaceutical is a specialty biopharmaceutical company focused on the development of first-to-market treatments for rare, genetic diseases. The company commercializes two enzyme replacement therapies for lysosomal storage disorders (LSD): Aldurazyme, a treatment for mucopolysaccharidoses I (marketed through a joint venture with Genzyme), and Naglazyme, a treatment for MPS VI.

Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Highlights

    BioMarin's product portfolio comprises two approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin.

    BioMarin derives its revenues from product sales of Naglazyme and Orapred; royalties related to the FDA approval of the marketing application for Orapred ODT; and license and contract research revenue under its agreement with Merck Serono. The company's total revenue increased from $19 million in 2004 to $ 84 million in 2006.

    BioMarin's major contributor to sales growth out to 2010 will be the product sales of Naglazyme, forecasted to increase at a CAGR of 60%, from $50 million in 2006 to $328 million in 2010. This represents an absolute growth of +279 million for the same period.

    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    TABLE OF CONTENTS
    Overview 1
    Catalyst 1
    Summary 1
    Company Structure 7
    Company Overview and Key Facts 7
    Business Description 8
    History 9
    Locations and Subsidiaries 11
    Company Financials 12
    Stock Market Performance 12
    P&L 13
    Balance Sheet 16
    Cash Flow 16
    Business Segment Performance 17
    Products & Services 19
    Marketed Products 19
    Pipeline Products 19
    Historical Product Sales 21
    AC Forecast Product Sales 21
    Competitors and Strategic Business Relationships 23
    Key Competitors 23
    Key Suppliers 23
    Key Clients 23
    Shareholding Structure 25
    Strategy 26
    Company View 26
    Corporate Strategy 27
    SWOT Analysis 29
    Overview 29
    Strengths 30
    Weaknesses 31
    Opportunities 32
    Threats 33
    Value Chain Analysis 35
    Overview 35
    Discovery and Product Development 35
    Manufacturing 36
    Sales 36
    Scorecard 37
    Overview 37
    Scorecard Analysis 38
    Key Employees 39
    List of Key Employees 39
    Key Employee Biographies 40
    Financial and Operational Overview 48
    Financial and Operational Overview 48
    APPENDIX 51
    Ask the analyst 51
    Datamonitor consulting 51
    Disclaimer 51


    TABLE OF FIGURES
    Figure 1: BioMarin Pharmaceutical - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 14
    Figure 2: BioMarin Pharmaceutical - Key Strategic Revenues, 2002-2006 ($ Mn) 18
    Figure 3: Biomarin Pharmaceutical - Key Strategic Revenues, 2006-2010 ($ Mn) 22


    TABLES
    Table 1: BioMarin Pharmaceutical - Key Facts 6
    Table 2: BioMarin Pharmaceutical – Locations and Subsidiaries 10
    Table 3: BioMarin Pharmaceutical - Year-End Share Price and Market Capitalization, 2002-2006 ($) 11
    Table 4: BioMarin Pharmaceutical - Key Events Impacting Share Price Performance 11
    Table 5: BioMarin Pharmaceutical - Operating revenue/cost analysis, 2002-2006 ($ Mn) 12
    Table 6: BioMarin Pharmaceutical - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 14
    Table 7: BioMarin Pharmaceutical - Balance Sheet, 2002-2006 ($ Mn) 15
    Table 8: BioMarin Pharmaceutical - Cash Flow, 2002-2006 ($ Mn) 15
    Table 9: BioMarin Pharmaceutical - Revenue Breakdown, 2002-2006 ($ Mn) 16
    Table 10: Biomarin Pharmaceutical - Marketed Products 18
    Table 11: Biomarin Pharmaceutical - In-house Pipeline Products 18
    Table 12: Biomarin Pharmaceutical - Historical Product Sales, 2002-2006 ($ Mn) 20
    Table 13: Biomarin Pharmaceutical - Forecast Sales, 2006-2010 ($ Mn) 20
    Table 14: Biomarin Pharmaceutical -– Key Competitors 22
    Table 15: Biomarin Pharmaceutical - Key Suppliers 22
    Table 16: Biomarin Pharmaceutical - Key Clients 23
    Table 17: BioMarin Pharmaceutical - Key Shareholders 24
    Table 18: BioMarin Pharmaceutical - SWOT Analysis Summary 28
    Table 19: BioMarin Pharmaceutical - Value Chain Analysis 34
    Table 20: BioMarin Pharmaceutical – Scorecard 36
    Table 21: BioMarin - Key Employees 38
    Table 22: Biomarin Pharmaceutical - Financial and Operational Overview 48